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bstract
Tissue transglutaminase (TG2) can induce post-translational modification of proteins, resulting in protein cross-linking or incorporation of
olyamines into substrates, and can also function as a signal transducing G protein. The role of TG2 in the formation of insoluble cross-links
as led to its implication in some neurodegenerative conditions. Exposure of pre-differentiated SH-SY5Y cells to the Parkinsonian neurotoxin
-methyl-4-phenylpyridinium ion (MPP+) resulted in significant dose-dependent reductions in TG2 protein levels, measured by probing Western
lots with a TG2-specific antibody. Transglutaminase (TG) transamidating activity, on the other hand, monitored by incorporation of a polyamine
seudo-substrate into cellular proteins, was increased. Inhibitors of TG (putrescine) and TG2 (R283) exacerbated MPP+ toxicity, suggesting that
ctivation of TG2 may promote a survival response in this toxicity paradigm.
2006 Elsevier Ireland Ltd. All rights reserved.
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oth environmental and genetic factors are implicated in the
poradic forms of Parkinson’s disease (PD), a disease charac-
erised by a profound loss of pigmented dopaminergic neurons in
he substantia nigra. Associated with this loss is the presence of
arge eosinophilic inclusions, Lewy bodies, containing a number
f proteins including-synuclein, neurofilaments, ubiquitin and
roteasomal elements. Genetic forms of the disease have sug-
ested roles for mitochondrial impairment [30], aggregation of
-synuclein [25], and defects in the ubiquitin–proteasome sys-
em [19]. Identification of the biochemical changes that induce
opaminergic cell death in PD is crucial to the development
f neuroprotective/restorative strategies. Mechanistically, tox-
ns that reproduce PD are directed against the electron transport
hain, and specifically inhibit complex 1 [3]. The most estab-
ished experimental model of PD is treatment with 1-methyl-4-
Abbreviations: MPP+, 1-methyl-4-phenylpyridinium ion; MPTP, 1-
ethyl-4-phenyl-1,2,3,6 tetrahydropyridine; PD, Parkinson’s disease; R283,
,3,dimethyl-2-[(2-oxopropyl) thio] imidazolium chloride; TG, transglutami-
ase; TG2, tissue transglutaminase
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henyl-1,2,3,6 tetrahydropyridine (MPTP), which via its active
etabolite 1-methyl-4-phenylpyridinium ion (MPP+) inhibits
omplex 1 and induces biochemical, pathological and symp-
omatic features with strong resemblance to PD [4,15,20].
Tissue transglutaminase (TG2) is a member of the transg-
utaminase (TG) family [14] and is endogenously expressed in
he CNS where it contributes to neural development, function
nd regeneration [22]. Post-translational modification of pro-
eins by TG2 causes protein cross-linking or incorporation of
olyamines into proteins. The reaction is calcium dependant
nd inhibited by GTP [13,22]. TG2 can also function as a sig-
al transducing G protein [11,24]. A major line of investigation
elates to the role of TG2 in cell survival and death pathways.
he ability of TG2 to modulate apoptotic pathways reportedly
epends greatly on the type of stimulus and, more specifically, its
ransamidating activity which was shown to modulate apoptosis
n the absence of changes in TG2 expression [27]. The ability
f TG2 to catalyse the formation of insoluble protein–protein
ross-links has led to its implication in neurodegenerative condi-
ions where insoluble inclusions characterise disease pathology,
ncluding Alzheimer’s disease [28] and Huntington’s disease
8]. Few studies have explored the link between TG2 and PD.
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owever, it has been previously reported that TG2 can mediate
-synuclein aggregation in vitro and, significantly, TG2 catal-
sed (-glutamyl)-lysine cross-links were found in the halo of
ewy bodies, co-localised with -synuclein, in PD and demen-
ia with Lewy bodies [17]. The purpose of this study was to
etermine whether TG2 has a role in MPP+ -induced toxicity.
Human SH-SY5Y neuroblastoma cells (ECACC, passages
8–20) were cultured in 90% (v/v) Dulbecco’s Modified Eagles
edium/Ham’s F12 (1:1), 2 mM l-glutamine, 1% (v/v) non-
ssential amino acids, 200 units/ml penicillin/0.2 mg/ml strep-
omycin, 10% (v/v) heat inactivated foetal bovine serum then
nduced to differentiate for 7 days with 10M all-trans retinoic
cid in the same medium except with 1% (v/v) FBS. Medium
as exchanged on days 3/4 and 7 after which experimental stud-
es were commenced.
Whole cell lysate was used for Western blotting with anti-
G2 (clone CUB-7402) antibody (Stratech Scientific Ltd.).
otal cell protein was extracted in extraction buffer (50 mM
rizma base, pH 6.8, 150 mM NaCl, 5 mM EDTA, 1% [w/v]
odium dodecylsulphate [SDS], 2 mM PMSF, 0.2% [v/v] pro-
ease inhibitor cocktail [Sigma–Aldrich Chemical Company,
K]). Extracts were sonicated (six pulses) on ice and boiled
or 1 min. Protein samples (30g) prepared in Lammeli’s sam-
le buffer were electrophoresed on SDS-polyacrylamide gels,
ransferred to nitrocellulose by Western blotting and probed
ith anti-TG2 (1:1000). Antibody binding was detected via
nhanced chemiluminescence (Amersham Biosciences, UK) in
ccordance with manufacturer’s guidelines. Band quantifica-
ion was performed using the GeneTools quantification system
Syngene, UK). To ensure equal protein loading, bands were
uantified and normalised against total ERK (as opposed to actin
r tubulin) due to the reported effects of MPP+ on cytoskeletal
roteins [5,29]. Total ERK levels remained constant following
PP+ exposures during the time courses used. To assess TG2
xpression by immunocytochemical analyses, cells were differ-
ntiated in permanox chamber slides over 7 days. Cells were
xed in 200l ice-cold 90% (v/v) methanol/TBS at −20 ◦C for
0 min. Cells were further permeabilised in 200l 0.5% (v/v)
riton X-100/PBS for 10 min at room temperature then incu-
ated with anti-TG2 antibody (1:20) overnight at 4 ◦C. Antibody
inding was detected with fluorescein isothiocyanate (FITC)
onjugated secondary antibody (1:50). Cell nuclei were stained
ith propidium iodide.
TG activity in control and MPP+ treated cells was deter-
ined using a method by Zhang et al. [33] (with modifications).
edium was supplemented with 2 mM EZ-link-5-(biotinamido)
entylamine (Perbio Science UK Ltd.), a pseudo-substrate
or TG, for the final hour of incubation. Total proteins were
xtracted, separated by SDS-PAGE and transferred to nitro-
ellulose by Western blotting. TG mediated incorporation of
Z-link-5-(biotinamido) pentylamine into proteins was detected
y probing nitrocellulose with neutravidin–HRP (2g/ml) and
evealed by a choice of enhanced chemiluminescence substrates.
n Fig. 2, ‘ECLTM Western Blotting Analysis System’ was used
Amersham Biosciences, UK), whilst in Fig. 3 ‘Supersignal
est Dura Extended Duration Substrate’ (Pierce, UK), which is
ore sensitive, was used.
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Cell viability was assessed using the 3-[4-5-dimethylthiazol-
-y1]-2,5-diphenyl tetrazolium bromide (MTT) reduction assay
or anchorage-dependent cells [9]. Viability was assayed in cells
ultured in 96-well plates where 10l 5 mg/ml MTT/PBS was
dded to the culture medium (100l) and incubated at 37 ◦C
n a humidified atmosphere of 95% air/5% carbon dioxide for
h. After this time, all medium was removed from the cells and
eplaced with 100l DMSO. The plate was then agitated on an
rbital shaker to dissolve the formazan product in the remaining
intact) cells. Absorbance was read at 570 nm.
To determine the effect of MPP+ on TG2 protein levels, pre-
ifferentiated cells were treated with 1 and 5 mM MPP+ (in
etinoic acid containing medium) for 24 h. Following extrac-
ion, proteins were fractionated by SDS PAGE, blotted onto
itrocellulose and probed with an anti-TG2 antibody. Fig. 1A
ndicates that 24 h exposure to 1 and 5 mM concentrations of
PP+ caused significant 30 and 70% reductions in TG2 expres-
ion, respectively. Immunocytochemical analysis (Fig. 1B, left
anel) shows that TG2 staining in differentiated cells was gen-
rally punctate and was present throughout the cell body and
xon-like processes, whilst low level staining was present in the
ucleus. Flow cytometry analysis of unpermeabilised SH-SY5Y
ells, using anti-TG2 antibody (clone CUB-7402), has revealed
hat the cells contain very low levels of extracellular TG2 (Griffin
nd Li, unpublished observations), consistent with the observa-
ions of Lesort et al. [21]. Following MPP+ exposure, the staining
attern of TG2 in differentiated cells was reduced and appeared
o localise predominantly around the nucleus (Fig. 1B, middle
nd right panels).
The ability of TG enzymes to catalyse the incorporation of
olyamines into proteins was exploited to determine whether
PP+ treatment evoked a change in TG activity. EZ-link-
-(biotinamido) pentylamine, a pseudo-substrate for TG was
dded to the medium where it became incorporated into cellular
roteins and then visualised by Western blotting. EZ-link-5-
biotinamido) pentylamine has been used previously to measure
ndogenous TG activity in SH-SY5Y cells in response to the
alcium-mobilising agent, maitotoxin [21]. Figs. 2 and 3A show
hat endogenous TG activity was increased in a dose-dependent
anner following MPP+ exposure, despite a reduction in TG2
rotein levels (Fig. 1A). To determine whether polyamine incor-
oration was indeed TG mediated, putrescine, a competitive
ubstrate for TG was added at a high concentration (10 mM)
o the cells, prior to addition of EZ-link-5-(biotinamido) penty-
amine. Amine incorporation following 1 mM MPP+ treat-
ent was reduced by approximately 74% in the presence of
utrescine, suggesting that it be, in part, mediated by TG activity
Fig. 2A). In Fig. 2B, we show the incorporation of EZ-link-5-
biotinamido) pentylamine into proteins induced by treatment
ith the calcium mobilising agent, ionomycin. Cells were pre-
oaded with the pseudo-substrate ± 10 mM putrescine for 1 h
rior to treatment with ionomycin for 15 min. Putrescine was
gain found to attenuate ionomycin-induced TG activity, reduc-
ng activity by approximately 79%. It was also observed that
he banding pattern following MPP+ treatment differed to that
nduced by ionomycin, suggesting that TG may preferentially
se different substrates depending on the insult.
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Fig. 1. TG2 expression is reduced following MPP+ treatment. Pre-differentiated SH-SY5Y cells were treated with 1 or 5 mM MPP+ for 24 h. TG2 was detected in
cell lysates by immunoblotting (A) or by immunocytochemistry (B) with anti-TG2 antibody. For panel A, bands were quantified and corrected against total ERK for
differences in protein loading. Results are presented as mean% of non-toxin treated cells (assigned 100%) ± S.E.M. for three (1 mM MPP+) and four (5 mM MPP+)
independent experiments, respectively. Statistical analysis of control vs. MPP+ treated cells was carried out using two-tailed t-tests where statistical significance was
accepted at **p < 0.01. For panel B, cells were differentiated on permanox chamber slides over 7 days. Medium was removed and replaced with fresh differentiating
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ith propidium iodide. Confocal analysis was performed at ×400 magnificatio
To substantiate that polyamine incorporation was mediated
y TG2, 1,3,dimethyl-2-[(2-oxopropyl) thio] imidazolium chlo-
ide (R283), a more specific and irreversible TG2 inhibitor,
irected to the active site of the enzyme [12], was employed.
olyamine incorporation following MPP+ treatment was dose-
ependently reduced by R283 (100 and 250M) (Fig. 3B).
ndeed, 250M R283 (a concentration which does not signifi-
antly affect cell viability; Fig. 4A) substantially reduced amine
d
j
5
smeabilised. Cells were probed with anti-TG2 antibody whilst nuclei are stained
le bar represents 20m.
ncorporation by 48% and 55% following treatment with 1 and
mM MPP+, respectively.
Further studies sought to determine the effect of TG inhi-
ition on MPP+ toxicity. Using the MTT reduction assay as a
eterminant of viability, cells were treated with MPP+ in con-
unction with putrescine (10 mM) or R283 (ranging from 50 to
00M). Results show that 5 mM MPP+ (but not 1 mM MPP+)
ignificantly reduced viability and that R283 alone did not affect
K.E. Beck et al. / Neuroscience Letters 405 (2006) 46–51 49
Fig. 2. TG activity is increased by MPP+ and ionomycin treatment and is attenuated by putrescine. (A) Pre-differentiated SH-SY5Y cells were treated with
M
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RPP+ ± 10 mM putrescine for 24 h. Cells were incubated with 2 mM EZ-link-5-(bio
oaded with 2 mM EZ-link-5-(biotinamido) pentylamine for 1 h prior to treatment wi
eparated on the same SDS-PAGE gel prior to transfer to nitrocellulose. TG mediated
y immunoblotting using neutravidin–HRP.
ig. 3. Increased TG activity following MPP+ exposure is partly mediated by TG2. P
4 h (A), and in the presence or absence of R283 (B). Medium was supplemented wi
ncorporation of EZ-link-5-(biotinamido) pentylamine into cells was detected by imm
esults were quantified and corrected against total ERK for differences in protein loadi
esults are the mean values of four independent experiments ± S.E.M.tinamido) pentylamine for the final hour. (B) Pre-differentiated cells were pre-
th 10M ionomycin for 15 min. Sample extracts were processed together and
incorporation of EZ-link-5-(biotinamido) pentylamine into cells was detected
re-differentiated SH-SY5Y cells were treated with 1 or 5 mM MPP+ alone for
th 2 mM EZ-link-5-(biotinamido) pentylamine for the final hour. TG mediated
unoblotting using neutravidin–HRP conjugated secondary antibody. For (A),
ng. Results are presented as mean% of non-toxin treated cells (assigned 100%).
50 K.E. Beck et al. / Neuroscience
Fig. 4. (A and B) Inhibition of TG2 exacerbates MPP+ toxicity. SH-SY5Y cells
were pre-differentiated in 96-well plates. On day 7 medium was exchanged
for fresh differentiation medium supplemented with putrescine or R283, 1 mM
MPP+ ± putrescine or R283, or 5 mM MPP+ ± putrescine or R283. After 24 h,
plates were assayed for viability using the MTT reduction assay. Data are
expressed as mean% of cells treated with corresponding inhibitor alone (assigned
100%) ± S.E.M. Data shown are combined from six independent experi-
ments (triplicate wells in each experiment). Statistical analysis of MPP+ vs.
MPP+ + inhibitor treated cells was performed using one-way ANOVA with Bon-
ferroni correction. Statistical significance was accepted at *p < 0.05, **p < 0.01
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Rr ***p < 0.001. Significant toxicity induced by 5 mM MPP+ alone compared to
re-differentiated control cells was shown (†p < 0.01).
iability except at the highest concentration (500M; Fig. 4A).
owever, both putrescine and R283 significantly exacerbated
oxicity by both 1 and 5 mM MPP+ (Fig. 4B).
Results presented propose a novel role for TG2 in MPP+
oxicity. TG2 expression following cytotoxic MPP+ exposure
as significantly reduced; it is possible that this may be
alpain-mediated since TG2 is a substrate for calpains [32] and
PTP/MPP+ has previously been shown to increase cytosolic
alcium levels, which would in turn activate calpain [7,18,29].
ndeed, treatment of mice with MPTP leads to increased cal-
ain mediated proteolysis whilst calpain inhibition attenuated
PTP toxicity [10]. It is widely accepted that MPP+ depletes
ellular ATP levels as a consequence of complex I inhibition
6,26]. If a parallel reduction in GTP ensued, TG2 activity could
ncrease. Indeed, it has previously been reported that mitochon-
rial function can lead to reduced GTP levels, associated with
ncreased TG activity in situ [23]. We observed that TG activity
as markedly increased following exposure to MPP+ despiteLetters 405 (2006) 46–51
reduction in TG2 protein levels; around half of this increase
n TG activity was mediated by TG2, being sensitive to R283.
t should be noted that uncoupling between enzyme expression
nd activity levels has also been reported under certain apoptotic
onditions [2].
The implications of elevated TG activity in MPP+ toxicity
re as yet unclear. MPP+ has the potential to up-regulate TG2
ctivity via a number of mechanisms; MPP+ has been reported
o increase ROS production [16] and increase intracellular cal-
ium levels, both factors that would increase TG2 activity [33].
pro-apoptotic role for TG2 was reported when transamidating
ctivity was elevated [27]. However, in the current study, a TG2
nhibitor in combination with MPP+ significantly exacerbated
PP+ toxicity, suggesting that the transamidating activity of
G2 has a pro-survival role in this instance. This is in line with a
tudy noting that the pro-survival, PI3-K pathway was necessary
or retinoic acid-induced TG2 expression and activity in NIH3T3
ells [1]. Furthermore, inhibition of TG2 caused retinoic acid to
ctivate apoptosis rather than differentiate the cells [1]. It should
e noted that whilst the cell culture system used in the cur-
ent project employs retinoic acid as a differentiation agent, TG
nhibitors exacerbated MPP+ toxicity at concentrations that had
o effect on the viability of control cells. In addition, a recent
tudy by Wakshlag et al. using differentiated SH-SY5Y cells
as shown that the role of TG activity varies according to insult
31]. They found that whilst TG activity augments the neuro-
oxic effects of -amyloid, it can also be protective against the
ytotoxic effect of hydrogen peroxide, in a similar way to that
ound for MPP+ in the present study. However, it remains to be
etermined whether the pro survival role of TG2 in our model is
ependent on its subcellular localisation, whether it is solely
ependent upon its transamidating function and whether the
TP hydrolysis/signal transduction activities are also involved.
dentification of proteins into which TG2 had mediated incorpo-
ation of polyamine in MPP+ treated cells would further define
he exact role of TG2 in MPP+ mediated toxicity. Whether pro-
eins located in Lewy bodies are natural substrates would be of
articular interest.
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